Osmotica Pharmaceuticals (NASDAQ:OSMT) received a $14.00 price target from investment analysts at Wells Fargo & Co in a research note issued to investors on Thursday, March 28th, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the stock. Wells Fargo & Co‘s price objective indicates a potential upside of 243.14% from the company’s previous close.
Shares of NASDAQ OSMT traded up $0.05 on Thursday, hitting $4.08. The company’s stock had a trading volume of 17,027 shares, compared to its average volume of 146,374. Osmotica Pharmaceuticals has a 12-month low of $3.54 and a 12-month high of $9.90. The company has a market capitalization of $210.21 million and a PE ratio of -8.00. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.51 and a quick ratio of 1.29.
Several hedge funds and other institutional investors have recently made changes to their positions in OSMT. Great Point Partners LLC purchased a new stake in shares of Osmotica Pharmaceuticals in the fourth quarter valued at about $11,625,000. Sphera Funds Management LTD. acquired a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at approximately $7,147,000. Broadfin Capital LLC acquired a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at approximately $4,096,000. BlackRock Inc. acquired a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at approximately $3,682,000. Finally, Millennium Management LLC acquired a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at approximately $2,568,000. 12.76% of the stock is currently owned by institutional investors.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: Roth IRA
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.